UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/025,167	12/19/2001	Patricia A. Billing-Medel	6068.US.D1	5842

23492 7590 02/05/2004

STEVEN F. WEINSTOCK
ABBOTT LABORATORIES
100 ABBOTT PARK ROAD
DEPT. 377/AP6A
ABBOTT PARK, IL 60064-6008

EXAMINER	
GOLDBERG, JEANINE ANNE	

ART UNIT	PAPER NUMBER
1634	

DATE MAILED: 02/05/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.	Applicant(s)	
	10/025,167	BILLING-MEDEL ET AL.	
	Examiner	Art Unit	
	Jeanine A Goldberg	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☒ Responsive to communication(s) filed on *11 November 2003*.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *7-10,12-14 and 16* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☒ Claim(s) *7-10,12-14 and 16* is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

13)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

a) ☐ The translation of the foreign language provisional application has been received.

14)☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

1) ☒ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____.
4) ☐ Interview Summary (PTO-413) Paper No(s). _____.
5) ☐ Notice of Informal Patent Application (PTO-152)
6) ☐ Other: .

DETAILED ACTION

1. This action is in response to the papers filed November 11, 2003. Currently, claims 7-10, 12-14, 16 are pending.

2. Any objections and rejections not reiterated below are hereby withdrawn.

3. This action contains new grounds of rejection necessitated by amendment.

4. It is noted that the examiner handling the instant application has changed. Please not the changes below.

Specification

5. The title of the invention is not descriptive of the elected invention. A new title is required that is clearly indicative of the invention to which the claims are directed.

Claim Objections

6. Claims 8-9 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form.

The claims are drawn to the particular means by which the polypeptide is produced, i.e. recombinant or synthetic techniques. These limitations do not appear to structurally change the polypeptide claimed in Claim 7.

Claim Rejections - 35 USC § 101

35 U.S.C. 101 reads as follows:

> Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

7. Claims 7-10, 12-14, 16 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility.

The claims are drawn to isolated polypeptides having at least 85% identity with SEQ ID NO: 41-49 and fragments thereof. The claims are also drawn to antibodies that specifically bind to a polypeptides where the polypeptide has at least 85% identity to an amino acid sequence of SEQ ID NO: 41-49 and fragments thereof. Also, methods of making polypeptide and antibodies are claimed.

The specification asserts that the polypeptides may be used to detect, diagnose, stage, monitor, prognosticate, prevent, treat, or determine predisposition to disease and conditions of the GI tract such as cancer (page 1, lines 12-15). The organs of the GI tract include the esophagus, stomach, small and large intestines, rectum and pancreas (page 1, lines 16-17).

The specification teaches ESTs were derived from cDNA libraries from GI tract tumor tissue, GI tract non-tumor tissues and numerous other tissues (page 51). The consensus sequence was found more than 82 times more often in GI tract than non GI tract tissues (page 51, lines 30-35). This statement does not discuss the presence or frequency of normal expression vs cancerous expression or diseased expression.

Example 4 is directed to ribonuclease protection assay, but no results are provided. Example 5 is directed to Northern Blotting but no results are provided. The additional examples are all drawn to methods well known in the art for studying genetic material, however there are no particular studies or assays performed using SEQ ID NO: 41-49. It is noted that SEQ ID NO: 41 is 917 amino acids in length. SEQ ID NO: 42-49 range from 15 amino acids to 40 amino acids in length.

The post-filing date art teaches polypeptides within the scope of the claims which have very significantly divergent functions. For example, WO200168848 teaches a amino acid sequence, namely SEQ ID NO: 129 which is 99.6% identical to SEQ ID NO: 41. The nucleic acid is taught to encode PRO polypeptides which are used to diagnose the presence of tumors such as colon, lung and prostate. Additionally, WO9963088 teaches a polypeptide sequence which 99.7% identical to SEQ ID NO: 41 which is described as having identity with a chloride channel protein and lung-endothelial cell adhesion molecule-1 that encodes a novel polypeptide. WO2003005024 teaches an amino acid sequence which is 99.8% identical to SEQ ID NO: 41 of the instant application. The CLCA4 protein is applicable to diagnosis and screening drugs for pulmonary and chest disease accompanied by inflammation in lung or airway and respiratory disease. WO200214366 teaches a nucleic acid which is 99.8% identical with SEQ ID NO: 41. The document teaches that the gene is involved in immune related responses observed with asthma. WO20020160382 teaches that a polypeptides which is 99.9% identical is expressed in colon cancer. It is clear from the post filing date art, that amino acids which are very similar to SEQ ID NO: 41, are not

useful for the same properties. The post filing date evidence does not appear to support the assertion that the instant amino acids may be used to detect, diagnose, stage, monitor, prognosticate, prevent, treat, or determine predisposition to disease and conditions of the GI tract such as cancer.

In the event that the polypeptides could be used to detect, diagnose, stage, monitor, prognosticate, prevent, treat, or determine predisposition to disease and conditions of the GI tract such as cancer (page 1, lines 12-15), this would not be a specific utility, as the GI tract encompasses very large numbers of diseases and conditions which the specification has not specifically pointed out. The statement in the specification regarding the general diagnostic utility for GI tract diseases is not sufficient since the specification has not disclosed what diseases may be diagnosed.

Further, the claimed polypeptides are not supported by a substantial utility because no substantial utility has been established for the claimed subject matter. For example, a polypeptide can be used to obtain an antibody. The antibody could then be used in conducting research to functionally isolate the protein. The need for such research clearly indicates that the protein and/or its function is not disclosed as to a currently available or substantial utility. A starting material that can only be used to produce a final product does not have substantial asserted utility in those instances where the final product is not supported by a specific and substantial utility. In this case, none of the antibodies that are to be produced as final products resulting from processes involving claimed polypeptides have specific and substantial utilities. The research contemplated by applicant(s) to characterize potential protein products,

especially their biological activities, does not constitute a specific and substantial utility. While the specification provides numerous studies which may be performed to determine the function and identity of the proteins claimed, the specification fails to provide any particular evidence to the function of the biological material. The skilled artisan would be required to perform further experimentation to reasonably confirm a "real world" context of use for the proteins and antibodies. The basic research required would be to study the properties of the claimed product itself to determine the mechanisms in which the material is involved. Identifying and studying the properties of a protein itself or the mechanisms in which the protein is involved does not define a "real world" context of use. Given the instant specification, there is no evidence the proteins are involved in the GI tract diseases, or how they may be used to diagnose/detect GI tract diseases. Prior to using the instant invention, the skilled artisan would be required to study the basic properties of the claimed invention to determine how to use the claimed invention in a meaningful and useful way. Similarly, the other listed and asserted utilities as summarized above or in the instant specification are neither substantial nor specific due to being generic in nature and applicable to a myriad of such compounds. It is noted that the post-filing date art which encompasses the claimed polypeptides and antibodies does not support the utility of diagnosing GI tract disorders.

Note, because the claimed invention is not supported by a specific and substantial asserted utility for the reasons set forth above, credibility of the utility has not been assessed.

Further experimentation would be required of the skilled artisan to determine a use for the polypeptides of the claimed invention. As noted by Brenner v. Manson, 383 US 519, 535-536 (1996), "Congress intended that no patents be granted on a chemical compound whose sole "utility" consists of its potential role as an object of use - testing... a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion."

Claim Rejections - 35 USC § 112- Enablement

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

8. Claims 7-10, 12-14, 16 are also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a specific or substantial asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

Factors to be considered in determining whether a disclosure meets the enablement requirement of 35 USC 112, first paragraph, have been described by the court in *In re Wands*, 8 USPQ2d 1400 (CA FC 1988). *Wands* states at page 1404, "Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized by the board in Ex parte Forman. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims."

The nature of the invention

The claims are drawn to isolated polypeptides having at least 85% identity with SEQ ID NO: 41-49 and fragments thereof. The claims are also drawn to antibodies that specifically bind to a polypeptides where the polypeptide has at least 85% identity to an amino acid sequence of SEQ ID NO: 41-49 and fragments thereof. Also, methods of making polypeptide and antibodies are claimed. The invention is in a class of invention which the CAFC has characterized as "the unpredictable arts such as chemistry and biology." Mycogen Plant Sci., Inc. v. Monsanto Co., 243 F.3d 1316, 1330 (Fed. Cir. 2001).

The breadth of the claims

The claims encompass any polypeptides with at least 85% identity, fragments or polypeptides minimally comprising a fragment of SEQ ID NO: 41-49. It is noted that SEQ ID NO: 41 is 917 amino acids in length. SEQ ID NO: 42-49 range from 15 amino acids to 40 amino acids in length. Therefore the claims further broadly encompass polypeptides which minimally contain 15 amino acids or minimally contain fragments of these polypeptides.

Quantity of Experimentation

The quantity of experimentation in this area is extremely large since determination of the polypeptides and antibodies would require, initially, in vitro studies to demonstrate proof of principle. That is, prior to any diagnostic or prognostic use, it would be necessary to determine how to make and use the claimed invention. The genus of genetic molecules encompassed by the claims is enormous. To begin experimentation, the skilled artisan would likely begin by determining how to use SEQ

ID NO: 41. The specification suggests using the polypeptide in diagnosis, treatment or prediction of GI tract diseases.

The organs of the GI tract include the esophagus, stomach, small and large intestines, rectum and pancreas (page 1, lines 16-17). Thus, GI tract diseases encompass cancers of the esophagus, stomach, small and large intestines, rectum and pancreas, or Crohn's disease, acid reflux problems, bowel movement disorders, etc. There are innumerable additional disease which are commensurate in scope with GI tract disorders.

While one could conduct additional experimentation to determine whether, e.g., presence, expression or amount of a polypeptide which has at least 85% identity with SEQ ID NO: 41-49 or a fragment thereof might be associated with, e.g., certain GI tract disorders, the outcome of such research cannot be predicted and such further research and experimentation are both unpredictable and undue.

The unpredictability of the art and the state of the art

The post-filing date art teaches polypeptides within the scope of the claims which have very significantly divergent functions. For example, WO200168848 teaches a amino acid sequence, namely SEQ ID NO: 129 which is 99.6% identical to SEQ ID NO: 41. The nucleic acid is taught to encode PRO polypeptides which are used to diagnose the presence of tumors such as colon, lung and prostate. Additionally, WO9963088 teaches a polypeptide sequence which 99.7% identical to SEQ ID NO: 41 which is described as having identity with a chloride channel protein and lung-endothelial cell adhesion molecule-1 that encodes a novel polypeptide.

WO2003005024 teaches an amino acid sequence which is 99.8% identical to SEQ ID NO: 41 of the instant application. The CLCA4 protein is applicable to diagnosis and screening drugs for pulmonary and chest disease accompanied by inflammation in lung or airway and respiratory disease. WO200214366 teaches a nucleic acid which is 99.8% identical with SEQ ID NO: 41. The document teaches that the gene is involved in immune related responses observed with asthma. WO20020160382 teaches that a polypeptides which is 99.9% identical is expressed in colon cancer. It is clear from the post filing date art, that amino acids which are very similar to SEQ ID NO: 41, are not useful for the same properties. The post filing date evidence does not appear to support the assertion that the instant amino acids may be used to detect, diagnose, stage, monitor, prognosticate, prevent, treat, or determine predisposition to disease and conditions of the GI tract such as cancer.

Working Examples

The specification has no working examples, whatsoever, of expression of SEQ ID NO: 41-49 or fragments thereof in tissues of GI tract disorders as compared to normal tissues.

Guidance in the Specification.

The specification, while providing a general review of various methods for detecting protein expression does not provide teachings sufficient to overcome doubts raised in the art. No specific teachings regarding the use of the particular SEQ ID NO: 41-49 with any success is presented. No teachings are provided to demonstrate to the skilled artisan how to use the sequences. It would essentially be a trial and error

process to make and use the diverse species of polypeptide molecules encompassed by the claims, and to use them satisfactorily. The teachings of the specification do not establish that one could actually detect SEQ ID NO: 41-49, proteins which are 85% identical to SEQ ID NO: 41-49, or fragments thereof as an indicator of GI tract diseases. Rather the teachings in the specification merely teach that the consensus sequence and fragments were found in 0.35% of the other, non-GI tract, libraries in the database. This does not provide any indication of the frequencies of the proteins in diseased vs normal tissues to provide guidance to the skilled artisan how to use the proteins to detect, diagnose, treat GI tract disorders. Further there is no indication of which GI tract disorders these proteins would be reasonably able to predispose, diagnose or treat an individual.

Level of Skill in the Art

The level of skill in the art is deemed to be high.

Conclusion

In the instant case, as discussed above, the level of unpredictability in the art is high, the specification provides one with no written description or guidance that leads one to a reliable use the polypeptides and antibodies. Thus given the broad claims in an art whose nature is identified as unpredictable, the unpredictability of that art, the large quantity of research required to define these unpredictable variables, the lack of guidance provided in the specification, the absence of any working examples and the negative teachings in the art balanced only against the high skill level in the art, it is the position of the examiner that it would require undue experimentation for one of skill in the art to perform the method of the claim as broadly written.

Claim Rejections - 35 USC § 112-Description

The following is a quotation of the first paragraph of 35 U.S.C. 112:

> The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

9. Claims 7-10, 12-14, 16 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

The claims are broadly drawn to isolated polypeptides having at least 85% identity with SEQ ID NO: 41-49 and fragments thereof. The claims are also drawn to antibodies that specifically bind to a polypeptides where the polypeptide has at least 85% identity to an amino acid sequence of SEQ ID NO: 41-49 and fragments thereof. Also, methods of making polypeptide and antibodies are claimed.

It is noted that SEQ ID NO: 41 is 917 amino acids in length. SEQ ID NO: 42-49 range from 15 amino acids to 40 amino acids in length. Therefore the claims further broadly encompass polypeptides which minimally contain 15 amino acids or minimally contain fragments of these polypeptides.

The post-filing date art teaches polypeptides within the scope of the claims which have very significantly divergent functions. For example, WO200168848 teaches a amino acid sequence, namely SEQ ID NO: 129 which is 99.6% identical to SEQ ID NO: 41. The nucleic acid is taught to encode PRO polypeptides which are used to diagnose

the presence of tumors such as colon, lung and prostate. Additionally, WO9963088 teaches a polypeptide sequence which 99.7% identical to SEQ ID NO: 41 which is described as having identity with a chloride channel protein and lung-endothelial cell adhesion molecule-1 that encodes a novel polypeptide. WO2003005024 teaches an amino acid sequence which is 99.8% identical to SEQ ID NO: 41 of the instant application. The CLCA4 protein is applicable to diagnosis and screening drugs for pulmonary and chest disease accompanied by inflammation in lung or airway and respiratory disease. WO200214366 teaches a nucleic acid which is 99.8% identical with SEQ ID NO: 41. The document teaches that the gene is involved in immune related responses observed with asthma. WO20020160382 teaches that a polypeptides which is 99.9% identical is expressed in colon cancer.

As provided in the Written Description Guidelines, Example 13 directed to protein variants, the specification and the claims do not indicate what distinguishing attributes are shared by the members of the genus. The limits placed upon the number of amino acid substitutions, deletions, insertions and/or addition that may be made to SEQ ID NO: 41-49 is limitless on the ends of the protein. Additionally the claims allow for 15% change between the sequences. Further, based upon the fragment language, the sequences will have very little similarity to the disclosed sequences. It is noted that the claim does not limit fragment to a particular length. Thus, a fragment of SEQ ID NO: 41 may comprise a "M." Thus, the scope of the claim includes numerous structural variants and the genus is highly variant because s significant number of structural differences between genus members is permitted. The claims would read on splice

variant proteins, homologous proteins, variant proteins, etc. As evidenced by the post-filing date art, applicant was not in possession of the claimed genus. Although the specification states that these types of changes are routinely done in the art, the specification and the claim do not provide any guidance as to what changes should e made. Structural features that could distinguish compounds in the genus from others in the protein class are missing from the disclosure. No common structural attributes identify the members of the genus. The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general guidance is what is needed. Since the disclosure fails to descry be the common attributes or characteristics that identify members of the genus, and because the genus is highly variant, SEQ ID NO: 41-49 alone is insufficient to describe the genus.

With regard to the antibody claims, one of skill in the art would have recognized that the spectrum of antibodies which bind to an amino acid sequence having at least 85% identity with SE QI DNO: 41-49 or a fragment thereof were not implicitly disclosed since the an amino acid sequence having at least 85% identity with SEQ ID NO: 41-49 or a fragment thereof was not thoroughly disclosed or isolated. Indeed, the court in Enzo Biochem v. Gen-Probe, Inc., 323 F.3d 956, 964 (Fed. Cir. 2002) ("Enzo Biochem II"), stated that "the written description requirement would be met for all of the claims [of the patent at issue] if the functional characteristic of [the claimed invention was] coupled with a disclosed correlation between that function and a structure that is sufficiently known or disclosed." The court adopted the USPTO Guidelines as persuasive authority for the proposition that a claim directed to "any antibody which is capable of binding to

antigen X" would have sufficient support in a written description that disclosed "fully characterized antigens." Synopsis of Application of Written Description Guidelines, at 60, available at http://www.uspto.gov/web/menu/written.pdf (last visited Jan. 16, 2003) (emphasis added). Therefore, based on our past precedent, as long as an applicant has disclosed a "fully characterized antigen," either by its structure, formula, chemical name, or physical properties, or by depositing the protein in a public depository, the applicant can then claim an antibody by its binding affinity to that described antigen. In cases where applicant fails to disclose the structural elements of the antibody or antigen, the applicant can not attempt to define an unknown by its binding affinity to another unknown. See Randolph J. Noelle v Seth Lederman, Leonard Chess and Michael J. Yellin (CAFC, 02-1187, 1/20/2004)(Interference No. 104,415).

One of skill in the art would reasonably conclude that the disclosure fails to provide a representative number of species to describe the genus. Thus, applicant was not in possession of the claimed genus.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

> A person shall be entitled to a patent unless –
>
> (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

10. Claims 7-9, 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Amersham Life Science Catalog 1994.

MPEP states 2113 that "[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process." In re Thorpe, 777 F.2d 695, 698, 227 USPQ 964, 966 (Fed. Cir. 1985) (citations omitted).

Amersham Catalog teaches amino acids including alanine, arginie, aspartic acid, glutamic acid, for example, which are fragments of SEQ ID NO: 41-49. Thus, the single amino acids anticipate the instant claims.

11. Claims 7-10, 12-14, 16 are rejected under 35 U.S.C. 102(b) as being anticipated by Cunningham et al. (J. Biological Chemistry, Vol. 270, No. 52, pages 31016-31026, 1995).

Cunningham et al. (herein referred to as Cunningham) teaches a nucleic acid, and protein sequence which comprises a fragment of SEQ ID NO: 41-49. For example, Cunningham teaches an amino acid which comprises the following amino acid sequence which is 100% identical with SEQ ID NO: 41, namely LLTDGEDN (amino acids at position 410-417 (limitations of Claim 7-9).

Cunningham teaches a fusion protein from a 570 bp BamHI fragment was used to culture a polypeptide in an expression system (limitations of Claim 12). The polypeptide was used to generate a rabbit polyclonal antibody (limitations of Claim 10, 13-14). It is noted that a polyclonal antibody consists of all epitopes in a protein. Therefore, the instant region is an epitope in the protein and would be inherently bound by the polyclonal antibodies taught in the art.

Thus, since Cunningham teaches every limitation of the instant claims, Cunningham anticipates the claimed invention.

Conclusion

12. No claims allowable.

13. Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jeanine Goldberg whose telephone number is (571) 272-0743. The examiner can normally be reached Monday-Friday from 6:00 a.m. to 3:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (571) 272-0745.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (571) 272-0507

J. Goldberg

Jeanine Goldberg
Patent Examiner
January 30, 2004